The role of Id-1 in chemosensitivity and epirubicin-induced apoptosis in bladder cancer cells

Oncology Reports

Volumn 21, Issue 4, 2009, Pages 1053-1059

  Hu, Hao ^a,b   Han, Hui Ying ^b   Wang, Yu Liang ^a   Zhang, Xiao Peng ^a   Chua, Chee Wai ^b   Wong, Y C ^b   Wang, Xiao Feng ^a   Ling, Ming Tat ^b   Xu, Ke Xin ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; Bladder cancer cells; Chemosensitivity; Epirubicin; Id 1

Indexed keywords

EPIRUBICIN; HELIX LOOP HELIX TRANSCRIPTION FACTOR ID 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; ID1 PROTEIN, HUMAN; INHIBITOR OF DIFFERENTIATION 1;

AGED; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CELL MIGRATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; WESTERN BLOTTING; BLADDER TUMOR; CELL MOTION; DRUG EFFECT; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; EPIRUBICIN; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 67449088929     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000323     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S and Huland H: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52: 1123-1130, 2007.
3. Chung PW, Bristow RG, Milosevic MF, Yi QL, Jewett MA, Warde PR, Catton CN, McLean M, Moore M, Tannock IF and Gospodarowicz MK: Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 25: 303-309, 2007.
4. Herr HW, Donat SM and Bajorin DF: Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 165: 811-814, 2001.
5. Xu N, Zhang XC, Xiong JP, Fang WJ, Yu LF, Qian J and Zhang L: A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium. BMC Cancer 7: 98, 2007.
6. Bamias A, Moulopoulos LA, Koutras A, Aravantinos G, Fountzilas G, Pectasides D, Kastritis E, Gika D, Skarlos D, Linardou H, Kalofonos HP and Dimopoulos MA: The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer 106: 297-303, 2006.
7. Benezra R, Davis RL, Lockshon D, Turner DL and Weintraub H: The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61: 49-59, 1990.
8. Fong S, Itahana Y, Sumida T, Singh J, Coppe JP, Liu Y, Richards PC, Bennington JL, Lee NM, Debs RJ and Desprez PY: Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci USA 100: 13543-13548, 2003.
9. Yuen HF, Chan YP, Chan KK, Chu YY, Wong ML, Law SY, Srivastava G, Wong YC, Wang X and Chan KW: Id-1 and Id-2 are markers for metastasis and prognosis in oesophageal squamous cell carcinoma. Br J Cancer 97: 1409-1415, 2007.
10. Schindl M, Oberhuber G, Obermair A, Schoppmann SF, Karner B and Birner P: Overexpression of Id-1 protein is a marker for unfavorable prognosis in early-stage cervical cancer. Cancer Res 61: 5703-5706, 2001.
11. Kamalian L, Gosney JR, Forootan SS, Foster CS, Bao ZZ, Beesley C and Ke Y: Increased expression of Id family proteins in small cell lung cancer and its prognostic significance. Clin Cancer Res 14: 2318-2325, 2008.
12. Li X, Zhang Z, Xin D, Chua CW, Wong YC, Leung SC, Na Y and Wang X: Prognostic significance of Id-1 and its association with EGFR in renal cell cancer. Histopathology 50: 484-490, 2007.
13. Ouyang XS, Wang X, Lee DT, Tsao SW and Wong YC: Overexpression of ID-1 in prostate cancer. J Urol 167: 2598-2602, 2002.
14. Ding Y, Wang G, Ling MT, Wong YC, Li X, Na Y, Zhang X, Chua CW, Wang X and Xin D: Significance of Id-1 upregulation and its association with EGFR in bladder cancer cell invasion. Int J Oncol 28: 847-854, 2006.
15. Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, Sharrocks AD, Peters G and Hara E: Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 409: 1067-1070, 2001.
16. Ling MT, Wang X, Ouyang XS, Lee TK, Fan TY, Xu K, Tsao SW and Wong YC: Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth. Oncogene 21: 8498-8505, 2002.
17. Ling MT, Wang X, Ouyang XS, Xu K, Tsao SW and Wong YC: Id-1 expression promotes cell survival through activation of NF-κB signaling pathway in prostate cancer cells. Oncogene 22: 4498-4508, 2003.
18. Wang X, Di K, Zhang X, Han HY, Wong YC, Leung SC and Ling MT: Id-1 promotes chromosomal instability through modification of APC/C activity during mitosis in response to microtubule disruption. Oncogene 27: 4456-4466, 2008.
19. Wong YC, Zhang XM, Ling MT and Wang XH: Inactivation of ID-1 gene induces sensitivity of prostate cancer cells to chemotherapeutic drugs. Adv Exp Med Biol 617: 565-572, 2008.
20. Cheung HW, Ling MT, Tsao SW, Wong YC and Wang X: Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 25: 881-887, 2004.
21. Ouyang XS, Wang X, Ling MT, Wong HL, Tsao SW and Wong YC: Id-1 stimulates serum-independent prostate cancer cell proliferation through inactivation of p16(INK4a)/pRB pathway. Carcinogenesis 23: 721-725, 2002.
22. Winquist E, Kirchner TS, Segal R, Chin J and Lukka H: Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 171 (2 Pt 1): 561-569, 2004.
23. Von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602-4608, 2005.
24. Hickman JA: Apoptosis and chemotherapy resistance. Eur J Cancer 32: A921-A926, 1996.
25. Zhang X, Ling MT, Wang X and Wong YC: Inactivation of Id-1 in prostate cancer cells: a potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway. Int J Cancer 118: 2072-2081, 2006.
26. Zhang X, Ling MT, Wong YC and Wang X: Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis. Cancer Sci 98: 308-314, 2007.